BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024
Rhea-AI Summary
BrainsWay (NASDAQ & TASE: BWAY), a leader in noninvasive neurostimulation treatments for mental health disorders, has announced its plan to report second quarter 2024 financial results on August 6, 2024, before U.S. financial markets open. The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss results and provide operational updates.
Investors can access the call via phone or webcast. The webcast will be available for replay for 30 days on BrainsWay's investor relations website. This announcement provides shareholders and analysts with a scheduled opportunity to review the company's financial performance and engage with management about recent developments and future prospects.
Positive
- None.
Negative
- None.
BURLINGTON, Mass. and JERUSALEM, July 23, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its second quarter 2024 financial results as well as operational highlights before the open of the U.S. financial markets on Tuesday, August 6, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
Conference Call Dial-In & Webcast Information:
| Date: | Tuesday, August 6, 2024 |
| Time: | 8:30 AM Eastern Time |
| United States: | 1-877-300-8521 |
| International: | 1-412-317-6026 |
| Israel: | 1-80-921-2373 |
| Conference ID: | 10190847 |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1679332&tp_key=1f7beb24a2 |
The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, https://investors.brainsway.com/events-and-presentations/event-calendar. Please access the Company’s website at least 10 minutes ahead of the conference call to register.
About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.
Contacts:
BrainsWay:
Ido Marom
Chief Financial Officer
Ido.Marom@BrainsWay.com
Investors:
Brian Ritchie
LifeSci Advisors LLC
britchie@lifesciadvisors.com
FAQ
When will BrainsWay (BWAY) report its Q2 2024 financial results?
What time is BrainsWay's (BWAY) Q2 2024 earnings call scheduled for?
How can investors access BrainsWay's (BWAY) Q2 2024 earnings call?
How long will the replay of BrainsWay's (BWAY) Q2 2024 earnings call be available?
